Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, is able to detect regions of damage and other disease-related features while using 60% less gadolinium — a chemical ...

QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult ...

an investigational gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). All QUANTI studies investigated gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body ...

QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult ...

QUANTI clinical development programme evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and across all ages In the ...

Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials.The QUANTI studies examined gadoquatrane at a ...

Computed tomography (CT), Magnetic resonance imaging (MRI), Ultrasound, Positron emission tomography), By Agent Type (Radiopharmaceuticals, Contrast Media, Magnetic Resonance Imaging (MRI) Contrast ...

Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational ...

The global contrast media injectors market is on a steady growth trajectory, with revenue projected to rise from USD 4,949 ...

Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, ...